Vi­core sells rights to IPF drug in Japan; Roche to lay off 340 work­ers; Sen­so­ri­on’s €50M of­fer­ing

Plus, news about Tenaya Ther­a­peu­tics, Ad­verum Biotech­nolo­gies, YS Bio­phar­ma, Evoke Phar­ma and BioX­cel Ther­a­peu­tics:

Nip­pon Shinyaku gets rights in Japan to IPF drug: The Japan­ese phar­ma com­pa­ny is pay­ing Vi­core Phar­ma $10 mil­lion up­front in a deal worth up to $275 mil­lion for Japan rights to C21, an an­giotensin II type 2 re­cep­tor ag­o­nist. Nip­pon Shinyaku is li­cens­ing the oral drug can­di­date for id­io­path­ic pul­monary fi­bro­sis, a chron­ic con­di­tion where the lungs be­come scarred and it’s hard for pa­tients to breathe. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER